This content originates from Baxter International Inc. prior to the company establishing its chronic kidney care and acute therapies businesses into one standalone company, Vantive. This content might contain references to products/brands/persons/services that are not applicable or relevant at the present time. Please contact us in case of any questions.
Baxter and Ayogo announce partnership for unique digital health solutions for home dialysis
Companies forge exclusive partnership to advance digital health solutions that educate and empower patients with kidney failure
The companies’ first mobile app, CKD&Me, launched in the United States; now preparing for global expansion
- Collaboration expected to also bring new patient mobile capabilities to Baxter’s Sharesource telehealth platform to support patient engagement and therapy management
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, and Ayogo Health Inc., a behavioral science-based digital health company, announced the expansion of their partnership to support the needs of patients with kidney disease through digital health solutions. Ayogo is combining LifePlan—its unique behavior-based digital platform—with Baxter’s expertise in renal care to build mobile apps and digital solutions that bring personalized, relevant and timely support to patients with kidney failure. Baxter also made an equity investment in Ayogo in exchange for minority interest in the company. Financial details of the agreement were not disclosed.
As a leader in renal care innovation and pioneer in digital health solutions for patients with kidney failure, our collaboration with Ayogo allows us to provide healthcare professionals and patients more confidence in their therapy options, including home dialysis,” said Laura Angelini, general manager, Baxter’s Renal Care business. “This is particularly important in the midst of the pandemic, when it is critical to support patients with digital health tools that empower them to perform dialysis in the safety of their home, while staying connected with their healthcare team.
Laura Angelini
General manager, Baxter’s Renal Care business
The companies’ initial collaboration resulted in a patient engagement app—CKD&Me—that provides customized disease and therapy education for the individual learning needs of patients with chronic kidney disease. CKD&Me recently launched in the United States for use on smartphones and tablets and is available in the United States on the App Store and on Google Play.
While the companies continue to expand the content and features of CKD&Me, they are also building a new mobile platform for patients using Baxter’s Sharesource remote patient management platform. Sharesource, which is widely used in 65 countries, has helped healthcare professionals remotely manage more than 17 million home patients’ dialysis treatments. The new initiative will provide patients the ability to more proactively manage their home dialysis therapy records in partnership with their healthcare team.
Two retrospective studies conducted at Baxter’s Renal Care Services clinics in Colombia found the use of Baxter’s Sharesource remote patient management platform with automated peritoneal dialysis (APD) therapy was associated with a 56% reduction in technique failure1 and a 39% reduction in hospitalizations.2 Both studies compared metrics for patients on APD and using Sharesource, with those of patients on APD but not using the remote patient management platform. Patients using Baxter’s APD systems with Sharesource to perform therapy can be closely monitored by their healthcare professionals without leaving their homes. Healthcare professionals can then act on this information by remotely adjusting their patients’ home device settings without requiring them to make additional trips to the clinic.
Ayogo’s vision is of an empowered patient, successful on their own terms, with tools and support dynamically tailored to the unique characteristics and circumstances of their life,” said Michael Fergusson, CEO, Ayogo. “We’re very excited that Baxter shares this vision. We’re proud of our collaboration on CKD&Me, and to grow our partnership with Baxter to bring the power of Sharesource and Ayogo’s LifePlan platform direct to patients around the world.
Michael Fergusson
CEO, Ayogo
About Vantive
Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. Today, patients across more than 100 countries around the world interact with Vantive’s people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility, efficiency and therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.
About Ayogo Health Inc.
Ayogo is an award-winning, behavioral science-based company, recently acknowledged as one of the 100 most innovative mHealth companies in the world. Ayogo’s Glimpse™ Platform substantially increases activation, adherence and persistence to therapy by tailoring content, tools and support to each person’s unique psychosocial characteristics. To learn more, visit www.ayogo.com and follow us on Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning CKD&Me and Sharesource, including availability and potential benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Baxter, CKD&Me and Sharesource are trademarks of Baxter International Inc.
References
-
Corzo Let al. Abstract “Clinical Outcomes in Remote Patient Monitoring Program in Automated Peritoneal Dialysis: A Colombian Experience.” 57th ERA-EDTA Virtual Congress, 2020. [P1151].
-
Sanabria M, et al. Remote Patient Monitoring Program in Automated Peritoneal Dialysis: Impact on Hospitalizations. Perit Dial Int. 2019;39(5):472-478. doi:10.3747/pdi.2018.00287.